Improving Standard of Care Through Variety

Alexander Bastian

Video Categories: ASH 2014

Alexander Bastian says the most important thing to come out of ASH that will improve standard of care is the variety of treatments coming available, including a new drug from Amgen for treating ALL.
December 18, 2018

Reimbursement Challenges and Solutions with Molecular Biomarker Testing

Drs. Geoffrey Oxnard and Lauren Ritterhouse consider the current landscape of reimbursement for molecular biomarker testing, the need to run FDA-approved tests, and the role of CMS and local Medicare providers in testing reimbursement.

November 10, 2012

PMO Interview with the Innovator Series: Volume 1

Deborah Dunsire, MD, President and CEO of Millennium: The Takeda Oncology Company, and Kathy Giusti, Founder and CEO of the Multiple Myeloma Research Foundation, discuss the issues and vision in improving personalized medicine strategies for patients with multiple myeloma.Deborah Dunsire, MD, is the former President and CEO of Millennium Pharmaceuticals, [ Read More ]